Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.57 |
| ▸ | DBH | P09172 | 3/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7316109 | 0.86 | PDE4B (0.74) | PDE4BALDH1A1GAAHSP90AA1 | |
| SCHEMBL7316582 | 0.83 | PDE4B (0.65) | PDE4BKMT2AALDH1A1SIGMAR1GAA | |
| SCHEMBL6156795 | 0.80 | CMA1 (0.53) | PDE4BKMT2AALDH1A1GAAMAPT | |
| SCHEMBL27871199 | 0.78 | MAPT (0.60) | KMT2ASIGMAR1MAPT | |
| SCHEMBL6159270 | 0.75 | PDE4B (0.76) | PDE4BKMT2AALDH1A1MAPT | |
| SCHEMBL7316530 | 0.75 | PDE4B (0.76) | PDE4BKMT2AALDH1A1CA2MAPT | |
| SCHEMBL29976282 | 0.75 | LMNA (0.51) | MAPK10KMT2AALDH1A1SIGMAR1CA2 | |
| SCHEMBL27629672 | 0.75 | CA1 (0.41) | PDE4BDBHALDH1A1CA2 | |
| SCHEMBL6159277 | 0.74 | APLNR (0.49) | PDE4BDBHKMT2AALDH1A1CA2 | |
| SCHEMBL7321239 | 0.74 | PDE4B (0.58) | PDE4BDBHGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403805-B1 | SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | disclosed |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2002-06-06 | — | — | US | disclosed |
| EP-0819122-B1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | disclosed |
| US-5994376-A | PHOSPHODIESTERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-11-30 | — | — | US | disclosed |
| EP-0819122-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031485-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | HRH2, CBR1, HRH1 | PDE4B 71/4885DBH 305/4885MAPK10 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.